Anderson M C, Baer H, Frazier D J, Quinnan G V
Office of Biologics Research and Review, Food and Drug Administration, Bethesda, MD 20892.
J Allergy Clin Immunol. 1987 Dec;80(6):861-8. doi: 10.1016/s0091-6749(87)80278-6.
Reactions after booster injections of human diploid cell rabies vaccine (HDCV) were investigated to determine the possibility of IgE-type antibody involvement. Although normal manufacture of HDCV involves the inactivation of the virus with beta-propiolactone (BPL), the effect of BPL on nonviral vaccine components, such as host cell components or stabilizing proteins, may be typical of the haptenic action of small molecular weight chemicals. Specific IgE to commercial HDCV preparations, BPL-treated preparations of noninfected host MRC5 cell sonicate (BPL-MRC5), and a human albumin (HA) (BPL-HA) used as a stabilizing agent were detected in sera from five individuals who reported reactions after booster doses of HDCV. However, these patients had no detectable IgE to normal HA. Sera from nonvaccinated individuals, vaccinated individuals who reported no reaction after HDCV booster, and pollen-allergic individuals had no detectable IgE to HDCV, BPL-MRC5, or BPL-HA. Changes in the ratios of pre- to postbooster serum levels of specific IgE to HDCV and BPL-HA were significantly different in a group of 19 individuals who reported reactions to HDCV boosters; these changes in pre- to postbooster IgE levels in nonreactive vaccinees were not significant. Prebooster serum IgE RAST ratios to HDCV or BPL-HA were not predictive of potential reactions to HDCV. A number of experimental BPL-HA reaction mixtures were assayed to examine the effect of variable concentrations of BPL to HA. Increasing relative molar concentrations of BPL to HA resulted in increased electrophoretic mobility, whereas the highest relative specific IgE binding was detected in BPL-HA molar reaction mixtures of approximately 12.5:1.(ABSTRACT TRUNCATED AT 250 WORDS)
研究了人二倍体细胞狂犬病疫苗（HDCV）加强注射后的反应，以确定IgE型抗体参与的可能性。虽然HDCV的正常生产涉及用β-丙内酯（BPL）使病毒失活，但BPL对非病毒疫苗成分（如宿主细胞成分或稳定蛋白）的作用可能是小分子化学物质半抗原作用的典型表现。在5名报告HDCV加强剂量后出现反应的个体血清中，检测到了针对市售HDCV制剂、经BPL处理的未感染宿主MRC5细胞超声裂解物（BPL-MRC5）以及用作稳定剂的人白蛋白（HA）（BPL-HA）的特异性IgE。然而，这些患者对正常HA没有可检测到的IgE。未接种疫苗的个体、接种HDCV加强针后未报告反应的个体以及花粉过敏个体的血清中，对HDCV、BPL-MRC5或BPL-HA均无可检测到的IgE。在一组19名报告对HDCV加强针有反应的个体中，加强注射前后血清中特异性IgE与HDCV和BPL-HA的水平比值变化显著不同；未出现反应的接种者加强前后IgE水平的这些变化不显著。加强注射前血清中HDCV或BPL-HA的IgE RAST比值不能预测对HDCV的潜在反应。检测了许多实验性BPL-HA反应混合物，以研究不同浓度BPL对HA的影响。BPL与HA相对摩尔浓度的增加导致电泳迁移率增加，而在约12.5:1的BPL-HA摩尔反应混合物中检测到最高的相对特异性IgE结合。（摘要截短于250字）
